Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

RIUMA. Repositorio Institucional de la Universidad de Málaga
Publication Artículo científico (JournalArticle)

An Exploratory Study on the Pathogenic Role of Faecal Extracellular Vesicles in Metabolic Dysfunction-Associated Steatotic Liver Disease Progression and in Drug-Induced Liver Injury

  • Ruiz-Malagón, Antonio J.
  • Herraiz-Vilela, Marina
  • Pinazo-Bandera, José
  • Toro-Ortiz, Juan Pedro
  • López-Gómez, Carlos
  • Ho-Plagaro, Ailec
  • Garrido-Sánchez, Lourdes
  • Robles-Díaz, María Mercedes
  • Taminiau, Bernard
  • Daube, Georges
  • Sanabria-Cabrera, Judith
  • Matilla-Cabello, Gonzalo
  • Lucena-González, María Isabel
  • Andrade-Bellido, Raúl Jesús
  • García-Fuentes, Eduardo
  • García-Cortés, Miren
  • Rodríguez-Díaz, Cristina
The role of extracellular vesicles secreted by the gut microbiota present in faeces (fEVs) is not well known in metabolic dysfunction- associated steatotic liver disease (MASLD) and idiosyncratic drug-induced liver injury (DILI). We identify the microbiome profiles of fEVs in these liver diseases, and analyse the effects of fEVs from MASLD, without (F ≤ 2) or with (F ≥ 3) significant liver fibrosis, and DILI patients on inflammation, steatosis and mitochondrial function. DILI patients showed a consistent pattern in fEVs, characterised by a decrease in Paraprevotella and an increase in AAP99, Acinetobacter, Actinobacillus, Aerococcus and Anaeroglobus . A higher presence of 16S rDNA was observed in plasma EVs from MASLD and DILI patients. HepG2 cells treated with DILI and MASLD F ≥ 3 fEVs increased TLR4 , TLR5 , IL6 and CASP3 expression, and accumulation of lipid droplets. DILI fEVs enhanced the hepatotoxic impact of diclofenac on the response to microbial components ( TLR4 , TLR5 ), inflammatory response ( IL1B , IL6 ), accumulation of lipid droplets and mitochondrial dysfunction ( OPA1 , DNM1L ). In conclusion, bacterial EVs enter the bloodstream and could modulate the immune response. DILI and MASLD F ≥ 3 fEVs are drivers of the pro-inflammatory response and hepatocyte steatosis. DILI fEVs have a distinct bacterial profile that enhances the hepatotoxic potential of diclofenac., Instituto de Salud Carlos III, Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía, Consejería de Salud, Junta de Andalucía, European Comission, Ministerio de Ciencia, Innovación y Universidades
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Membrane Vesicles of Toxigenic Clostridioides difficile Affect the Metabolism of Liver HepG2 Cells

  • Caballano-Infantes, Estefanía
  • Ho-Plagaro, Ailec
  • López-Gómez, Carlos
  • Martín-Reyes, Flores
  • Rodríguez-Pacheco, Francisca
  • Taminiau, Bernard
  • Daube, Georges
  • Garrido-Sánchez, Lourdes
  • Alcaín-Martínez, Guillermo
  • Andrade, Raúl J.
  • García-Cortés, Miren
  • Lucena, M. Isabel
  • García-Fuentes, Eduardo
  • Rodríguez-Díaz, Cristina
Clostridioides difficile infection (CDI) appears to be associated with different liver diseases. C. difficile secretes membrane vesicles (MVs), which may be involved in the development of nonalcoholic fatty liver disease (NALFD) and drug-induced liver injury (DILI). In this study, we investigated the presence of C. difficile-derived MVs in patients with and without CDI, and analyzed their effects on pathways related to NAFLD and DILI in HepG2 cells. Fecal extracellular vesicles from CDI patients showed an increase of Clostridioides MVs. C. difficile-derived MVs that were internalized by HepG2 cells. Toxigenic C. difficile-derived MVs decreased mitochondrial membrane potential and increased intracellular ROS compared to non-toxigenic C. difficile-derived MVs. In addition, toxigenic C. difficile-derived MVs upregulated the expression of genes related to mitochondrial fission (FIS1 and DRP1), antioxidant status (GPX1), apoptosis (CASP3), glycolysis (HK2, PDK1, LDHA and PKM2) and β-oxidation (CPT1A), as well as anti- and pro-inflammatory genes (IL-6 and IL-10). However, non-toxigenic C. difficile-derived MVs did not produce changes in the expression of these genes, except for CPT1A, which was also increased. In conclusion, the metabolic and mitochondrial changes produced by MVs obtained from toxigenic C. difficile present in CDI feces are common pathophysiological features observed in the NAFLD spectrum and DILI., This work was supported in part by a grant from the Instituto de Salud Carlos III (Spain) (PI18/01652, PI19/00883 and PI21/01248), and from the Consejería de Economía, Conocimiento, Empresas y Universidad (Junta de Andalucía, Spain) (PI18-RT-3364 and UMA18-FEDERJA-194). This study has been co-funded by FEDER funds (“A way to make Europe”) (“Andalucía se mueve con Europa”). CRD is supported by a grant from the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de Junta de Andalucía (Spain) (DOC_01610). FMR is supported by a grant from the ISCIII (Spain) (FI19/00189). CLG is supported by a grant from the ISCIII (CP22/00050) (Spain). FRP is supported by the Miguel Servet program from the ISCIII (Spain) (CP18/00042). LGS is supported by the Nicolas Monardes program from the Consejería de Salud de Andalucía (Spain) (C-0028-2018). EGF is supported by the Nicolas Monardes program from the Consejería de Salud de Andalucía (Spain) (RC-0005-2020)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

  • Lucena, M. Isabel
  • Villanueva-Paz, M.
  • Álvarez-Álvarez, I.
  • Aithal, G. P.
  • Björnsson, E. S.
  • Cakan-Akdogan, G.
  • Cubero, Francisco Javier
  • Esteves, F.
  • Falcón-Pérez, Juan M.
  • Fromenty, B.
  • García-Ruiz, Carmen
  • Grove, J. I.
  • Konu, O.
  • Kranendonk, M.
  • Kullak-Ublick, G. A.
  • Miranda, Joana
  • Remesal-Doblado, A.
  • Sancho-Bru, P.
  • Nelson, L.
  • Andrade, Raúl J.
  • Daly, A. K.
  • Fernández-Checa, José C.
In the current article the aims for a constructive way forward in Drug-Induced Liver Injury (DILI) are to highlight the most important priorities in research and clinical science, therefore supporting a more informed, focused, and better funded future for European DILI research. This Roadmap aims to identify key challenges, define a shared vision across all stakeholders for the opportunities to overcome these challenges and propose a high-quality research program to achieve progress on the prediction, prevention, diagnosis and management of this condition and impact on healthcare practice in the field of DILI. This will involve 1. Creation of a database encompassing optimised case report form for prospectively identified DILI cases with well-characterised controls with competing diagnoses, biological samples, and imaging data; 2. Establishing of preclinical models to improve the assessment and prediction of hepatotoxicity in humans to guide future drug safety testing; 3. Emphasis on implementation science and 4. Enhanced collaboration between drug-developers, clinicians and regulatory scientists. This proposed operational framework will advance DILI research and may bring together basic, applied, translational and clinical research in DILI., The present study has been supported by grants from Instituto de Salud Carlos III (ISCIII) (contract numbers: PID2022–140169OB-C21; PI21/01248; PI19/00883) and from Consejería de Salud de Andalucía (contract number: PEMP-0127–2020, Spain), cofounded by the European Union. This research was funded by HORIZON-HLTH-2022-STAYHLTH-02, grant number 101095679. Funded by the European Union. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. MK was partially supported by Grant UID/BIM/0009/2020 of the Portuguese Fundação para a Ciência e a Tecnologia (FCT). MVP and IAA hold Sara Borrell research contracts from ISCIII (CD21/00198 and CD20/00083, respectively). This research was supported by CIBERehd – Consorcio Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund. JIG and GPA are supported by NIHR Nottingham Biomedical Research Centre [NIHR203310]. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. This publication is based upon work from COST Action “CA17112—Prospective European Drug-Induced Liver Injury Network” supported by COST (European Cooperation in Science and Technology); www.cost.eu., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

  • Stephens, Camilla|||0000-0002-0796-9610
  • Robles Díaz, Mercedes|||0000-0002-2365-2787
  • Medina-Cáliz, Inmaculada|||0000-0003-0471-6658
  • Garcia-Cortes, Miren|||0000-0003-0410-8273
  • Ortega-Alonso, Aida|||0000-0002-8999-4093
  • Sanabria-Cabrera, Judith|||0000-0002-7769-7008
  • Gonzalez-Jimenez, Andrés
  • Alvarez-Alvarez, Ismael
  • Slim, Mahmoud|||0000-0003-2455-1432
  • Jimenez-Perez, Miguel
  • Gonzalez-Grande, Rocio
  • Fernández, M.Carmen
  • Casado, Marta
  • Soriano, German|||0000-0002-9267-6811
  • Roman, Eva|||0000-0001-9084-8555
  • Hallal, Hacibe
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Castiella, Agustin
  • Conde, Isabel|||0000-0001-7863-2233
  • Prieto, Martin
  • Moreno-Planas, Jose Maria
  • Giraldez, Alvaro
  • Moreno-Sanfiel, J.Miguel
  • Kaplowitz, Neil
  • Lucena, M. Isabel|||0000-0001-9586-4896
  • Andrade, Raúl J.
  • Cortés, M.G.
  • Pinazo, Jose
  • García Muñoz, B.
  • Alcántara, Ramiro
  • Hernández, Andrés
  • Escaño, M.D.García
  • del Campo, E.
  • González-Jiménez, A.
  • Sanjuán Jiménez, Rocío
  • Cueto, Alejandro
  • Bonilla, Elvira
  • Di Zeo, D.
  • Niu, H.
  • Villanueva-Paz, Marina|||0000-0003-4728-201X
  • Papineau, A.
  • Pérez Hernández, Manuel José
  • González-Grande, Rocío|||0000-0002-7691-5755
  • López Ortega, S.
  • Santaella, I.
  • Ocaña, A.
  • Palomino, P.
  • Fernández, Maria Carmen
  • Peláez, Gloria
  • Porcel, A.
  • Casado, M.
  • González Sánchez, Mara
  • Millán-Domínguez, R.
  • Fombuena, Blanca
  • Gallego, Rocío
  • Ampuero, Javier|||0000-0002-8332-2122
  • Del Campo, José Antonio
  • Calle-Sanz, R.
  • Rojas, Lourdes
  • Rojas, Ángela|||0000-0003-0853-4800
  • Gil Gómez, Alexandra
  • Vilar, Eduardo
  • Guarner, Carlos|||0000-0001-5957-9481
  • Quijada-Manuitt, María Ángeles|||0000-0002-9624-0177
  • Antonijoan Arbós, Rosa Ma|||0000-0002-7099-5125
  • Sánchez Delgado, Jordi|||0000-0002-5217-6492
  • Vergara Gómez, Mariano
  • Hallal, H.
  • García Oltra, Ester
  • Titos Arcos, J.C.
  • Pérez Martínez, Alfonso
  • Sánchez Cobarro, C.
  • Egea Caparrós, J.M.
  • Zapata, Eva María
  • Arenas, Juan Ignacio
  • Gómez García, Alexandra
  • Esandi, F.J.
  • Blanco, Sonia
  • Martínez Odriozola, Pedro
  • Crespo García, Javier|||0000-0001-8248-0172
  • Iruzubieta, Paula|||0000-0001-9476-1801
  • Cabezas González, Joaquín|||0000-0003-0012-484X
  • Giráldez Gallego, Álvaro
  • Rodríguez Seguel, Elisa
  • Cuaresma, María
  • González-Gallego, Javier|||0000-0002-4386-9342
  • Jorquera, Francisco|||0000-0002-1799-2881
  • Sánchez Campos, S.
  • Otazua, Pedro
  • de Juan Gómez, A.
  • Salmerón, Javier
  • Gila, Ana
  • Quiles, Rosa
  • González, José Manuel
  • Lorenzo, Sara
  • Prieto, Martín
  • Conde Amiel, I.
  • Berenguer, Marina|||0000-0001-9246-4264
  • García-Eliz, María
  • Primo, Joaquín
  • Molés, José Ramón
  • Garayoa, Ana
  • Carrascosa, Miguel
  • Gómez Domínguez, Elena
  • Cuevas, L.
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Montané Esteva, Eva|||0000-0002-1691-7652
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Arellano, Ana Lucía|||0000-0001-8601-3504
  • Sanz, Yolanda
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Sala, Margarita
  • Masnou Ridaura, H.
  • Bruguera, Miquel
  • Ginès, Pere|||0000-0003-4657-4504
  • Lens, Sabela|||0000-0003-4900-411X
  • Mariño, Zoe|||0000-0001-6321-9534
  • Hernández Guerra, Manuel
  • Moreno Sanfiel, J.M.
  • Fernández del Campo, C.Boada
  • Tejedor, Martián
  • González Ferrer, Ruth
  • Fernández, Conrado
  • Fernández Gil, Marta
  • Montero, José Luís
  • de la Mata, Manuel
  • Fuentes Olmo, Javier|||0000-0001-8637-510X
  • Fernández Bonilla, E.M.
  • Moreno, Julián M.
  • Martínez-Ródenas, Ponciano
  • Gómez Garrido, M.
  • Oliva, C.
  • Rendón, Paloma|||0000-0002-6521-3766
  • García Samaniego, Javier
  • Madejón, Antonio
  • Calleja, Jose Luis|||0000-0002-2265-6591
  • Martínez Porras, J.L.
  • Cabriada, José Luis|||0000-0002-3068-5659
  • Pérez-Moreno, José Manuel
  • Lara, Carmen
Background & Aims: Prospective drug-induced liver injury (DILI) registries are important sources of information on idiosyncratic DILI. We aimed to present a comprehensive analysis of 843 patients with DILI enrolled into the Spanish DILI Registry over a 20-year time period. Methods: Cases were identified, diagnosed and followed prospectively. Clinical features, drug information and outcome data were collected. Results: A total of 843 patients, with a mean age of 54 years (48% females), were enrolled up to 2018. Hepatocellular injury was associated with younger age (adjusted odds ratio [aOR] per year 0.983; 95% CI 0.974-0.991) and lower platelet count (aOR per unit 0.996; 95% CI 0.994-0.998). Anti-infectives were the most common causative drug class (40%). Liver-related mortality was more frequent in patients with hepatocellular damage aged ≥65 years (p = 0.0083) and in patients with underlying liver disease (p = 0.0221). Independent predictors of liver-related death/transplantation included nR-based hepatocellular injury, female sex, higher onset aspartate aminotransferase (AST) and bilirubin values. nR-based hepatocellular injury was not associated with 6-month overall mortality, for which comorbidity burden played a more important role. The prognostic capacity of Hy's law varied between causative agents. Empirical therapy (corticosteroids, ursodeoxycholic acid and MARS) was prescribed to 20% of patients. Drug-induced autoimmune hepatitis patients (26 cases) were mainly females (62%) with hepatocellular damage (92%), who more frequently received immunosuppressive therapy (58%). Conclusions: AST elevation at onset is a strong predictor of poor outcome and should be routinely assessed in DILI evaluation. Mortality is higher in older patients with hepatocellular damage and patients with underlying hepatic conditions. The Spanish DILI Registry is a valuable tool in the identification of causative drugs, clinical signatures and prognostic risk factors in DILI and can aid physicians in DILI characterisation and management. Lay summary: Clinical information on drug-induced liver injury (DILI) collected from enrolled patients in the Spanish DILI Registry can guide physicians in the decision-making process. We have found that older patients with hepatocellular type liver injury and patients with additional liver conditions are at a higher risk of mortality. The type of liver injury, patient sex and analytical values of aspartate aminotransferase and total bilirubin can also help predict clinical outcomes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries

  • Medina-Cáliz, Inmaculada|||0000-0003-0471-6658
  • Sanabria-Cabrera, Judith|||0000-0002-7769-7008
  • Villanueva-Paz, Marina|||0000-0003-4728-201X
  • Aukštikalnė, Lauryna
  • Stephens, Camilla|||0000-0002-0796-9610
  • Robles Díaz, Mercedes|||0000-0002-2365-2787
  • Pinazo-Bandera, José M.
  • García-Cortes, Miren
  • Conde, Isabel|||0000-0001-7863-2233
  • Soriano, German|||0000-0002-9267-6811
  • Bessone, Fernando
  • Hernandez, Nelia
  • Nunes, Vinicius
  • Paraná, Raymundo
  • Lucena, M. Isabel|||0000-0001-9586-4896
  • Andrade, Raúl J.
  • Niu, Hao
  • Alvarez-Alvarez, Ismael
Idiosyncratic drug-induced liver injury (DILI) associated with drug reactions with eosinophilia and systemic symptoms (DRESS) is poorly characterized among patients of Western countries. We aimed to comprehensively assess the clinical characteristics, outcomes, and causative agents in a prospective, well-vetted cohort of DILI patients with DRESS (DILI-DRESS). We identified 53 DILI-DRESS cases from the Spanish DILI Registry and the Latin American DILI Network. For comparison purposes, we defined a group of DILI patients (n = 881). DILI-DRESS cases were younger (47 vs. 53 years, respectively; p = 0.042) and presented more frequently with cholestatic/mixed damage (p = 0.018). Most DILI-DRESS patients showed moderate liver injury, 13% developed severe damage, and only one patient (with hepatocellular injury due to anti-tuberculosis drugs) progressed to acute liver failure and died. DILI-DRESS cases showed a distinctive causative drug pattern compared to DILI cases. The most frequent drugs were carbamazepine (13%), anti-tuberculosis drugs (13%), amoxicillin-clavulanate (11%), and allopurinol and lamotrigine (7.6% each). Among all cases of DILI due to allopurinol and lamotrigine, 67% presented with a DILI-DRESS phenotype, respectively. Higher total bilirubin (TBL) levels at DILI recognition (odds ratio [OR] 1.23; 95% confidence interval [CI] 1.04-1.45) and absence of eosinophilia (OR 8.77; 95% CI 1.11-69.20) increased the risk for developing a severe-fatal injury in DILI-DRESS patients. DILI-DRESS patients have a more frequent cholestasis/mixed pattern of injury at presentation, with antiepileptics as distinctive causative drug class. Most of the lamotrigine and allopurinol cases present with this phenotype. Higher TBL levels and absence of eosinophilia at DILI recognition are markers of poor outcomes.